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district level. CONCLUSION: This approach seem to be an
original, robust and reproducible technique for risk assessment
purpose, which can be applied to a number of diseases and
technology assessment when the number of indicators (risk indi-
cators, clinical indicators, biologic indicators, etc) make data
interpretation, comparisons and decision making difﬁcult.
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MRSA: INVESTIGATINGTHE DANGEROUS HOSPITAL
INFECTION
Glassford RJ
University of Louisville, Louisville, KY, USA
OBJECTIVE: Methicillin-resistant Staphylococcus aureus, or
MRSA, is a commonly acquired infection in the hospital envi-
ronment. We examine data from the National Inpatient Sample
(NIS) to diagnose trends to gain more insight about the infection.
It is the purpose of this study to determine if race, age or gender
are factors in the severity of the infection, and to ascertain what
effects any secondary conditions may have on a patient with
MRSA. METHODS: The data were collected from a 10%
sample from 2004 from the NIS with information relevant to
5974 patients diagnosed with MRSA. The data were then
imported into SAS Enterprise Guide 4. SAS is used to create
tables of data and kernel density estimates, which give an esti-
mate of the data’s probability density, to develop a logistic regres-
sion model relating death risk to speciﬁc diagnoses, and to
develop a linear model concerning a patient’s total charges.
RESULTS: There appears to be a correlation between the age of
a patient and the length of inpatient stay. Asian American and
African American patients experience a higher mortality rate
with MRSA. Total charges were similar between males and
females, although males showed a slightly higher mean; second-
ary conditions and age had a much more pronounced effect on
charges. The three most common conditions present in patients
with MRSA were hypertension, urinary tract infection (UTI), and
congestive heart failure—UTI and heart failure appear to raise
the risk of death to one with MRSA. CONCLUSIONS: Further
studies should be conducted to investigate MRSA and how it
affects people from various ethnic backgrounds and age groups.
By analyzing medical data and performing kernel density esti-
mates, it is possible to uncover important relationships that can
be used to treat patients worldwide.
INFECTION—Cost Studies
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OBJECTIVE: Quantify the budgetary impact of adding a new
carbapenem, doripenem, to a hospital formulary for treatment
of complicated intra-abdominal infection (cIAI), complicated
urinary tract infection (cUTI) and nosocomial pneumonia (NP)
including ventilator-associated pneumonia (VAP), in the United
States. Doripenem has been approved in the US for cIAI and
cUTI and is under FDA review for treatment of NP, including
VAP. METHODS: This model was developed in accordance with
Good Research Practices for Budget Impact Analysis dissemi-
nated by ISPOR to estimate the annual impact on a hospital’s
budget of adding doripenem. Carbapenem (doripenem, imi-
penem, meropenem) wholesale acquisition costs from 2007
National Drug Data File, hospitalization costs (2006 US dollars)
from published literature, annual hospital admissions for NP,
VAP, cIAI, and cUTI, current proportional share of imipenem
and meropenem (50% each, no doripenem use), treatment dura-
tion and length of stay (LOS) from clinical trials were considered.
A new proportional share of 50% doripenem, 30% imipenem
and 20% meropenem was assumed for this analysis. Sensitivity
of results on different proportions of doripenem use was exam-
ined. RESULTS: Total cost per treated patient was estimated to
be $24,284 (range: $13,117 (cUTI) to $71,026 (VAP)), prior to
introduction of doripenem. With the new proportional share, it
would decrease to $23,305 (range: $12,987 (cUTI) to $65,289
(VAP)), a 4% reduction in the budget. Pharmacy costs made up
4% of overall treatment costs. The majority of savings came
from shorter hospital LOS for VAP, observed in clinical trials
comparing doripenem to comparators. Scenarios with a greater
proportion of doripenem use resulted in larger savings to the
hospital budget ($1927 per patient at 100% doripenem use).
Results remained favorable for formulary with doripenem under
various sensitivity analyses. CONCLUSION: Results indicate
that adding doripenem to a hospital formulary will yield poten-
tial savings to a hospital’s budget.
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OBJECTIVE: To quantify the workforce and cost implica-
tions of routine doctor-intensive (DI), nurse-intensive (NI) and
pharmacist-intensive (PI) ART follow-up algorithms for HIV/
AIDS treatment at the Infectious Diseases Institute, a large
urban HIV clinic in Kampala, Uganda. METHODS: We per-
formed a societal perspective cost analysis including health
resource utilization and opportunity cost of patient waiting
(PW) time. A time-motion survey was performed to estimate
median health worker utilization (HWU) and PW times for dif-
ferent services. Unique personnel requirements were identiﬁed
to determine hourly HWU per patient, which was multiplied by
hourly wages for different cadres. PW times were multiplied by
mean hourly wage for Ugandans. National workforce and cost
implications were projected. RESULTS: Median HWU and PW
times per visit (hours) were 0.20 and 0.24 for triage nurses,
0.12 and 1.10 for doctors, 0.08 and 0.27 for pharmacists, and
0.13 and 0.05 for nurses. HWU time for reﬁll pharmacists
was 0.03 with no waiting. Hourly wages were: nurses-$4.6,
doctors-$8.3, and pharmacists-$3.3. The average Ugandan
hourly wage was $0.99. Total annual societal per-patient cost
of follow-up was $45.2 for DI, $28.3 for NI and $16.3 for PI.
Total projected national annual follow-up cost was $13.5
million for DI, $8.5 million for NI and $4.9 million for PI.
Extrapolating to a national level, we project that the substitu-
tion of nurses or pharmacists for doctors would save 404 full-
time-equivalent doctors per year, 18.4% of the current
number practicing in Uganda. CONCLUSION: The use of NI
and PI innovations as substitutes for DI follow-up results in
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substantial reductions in doctor demand and substantial soci-
etal cost savings. Since prior research suggests no adverse
impact on adherence to drugs and follow-up of these innova-
tions, serious consideration should be given to policy changes
to adopt substituting for doctor for routine HIV follow-up
care.
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OBJECTIVE: To evaluate all-cause mortality and cost of treat-
ment in patients with refractory invasive aspergillosis (rIA)
treated with either posaconazole or other systemic anti-fungal
(SAF) therapies. METHODS: All-cause mortality and cost of
salvage therapy of posaconazole oral suspension (800 mg/day)
and other SAF treatments were assessed using a multicenter
clinical study in patients with IA refractory to or intolerant of
conventional antifungal therapy. Data from external controls
were collected retrospectively providing a comparative refer-
ence group. All patients had failed to improve or progress with
prior SAF therapies. Prior SAF treatments for the majority of
patients were liposomal amphotericin B, amphotericin B, or
itraconazole. Cases of aspergillosis deemed evaluable by a
blinded data review committee included 107 posaconazole and
86 control subjects (modiﬁed intent-to-treat population). The
populations were comparable regarding pre-speciﬁed demo-
graphic and clinical characteristics. All-cause mortality were
analyzed using the survival technique. Economic evaluations
were conducted using survival data and costs of pharmaco-
therapy one year post therapy (2007 Canadian dollars).
RESULTS: Signiﬁcantly more posaconazole-treated patients
responded to therapy as compared with other SAF therapies.
Patients with rIA treated with posaconazole appeared to confer
a highly signiﬁcant survival beneﬁt over the control cases. The
cumulative rates of survival at 30 days and at the end of
therapy were 74% and 38%, respectively. For controls, those
survival rates were 49% and 22%, respectively. The Kaplan-
Meier survival curves were signiﬁcantly different (P = 0.0003).
In addition, posaconazole appeared to be a cost-saving option
for the treatment of rIA compared with the active comparator
receiving standard SAF treatments ($14,839 vs. $38,158). Sen-
sitivity analyses demonstrated the robustness of the results
over a range of alternative values for costs and outcomes.
CONCLUSION: Treatment with posaconazole compared with
other SAF treatments provided a signiﬁcant survival beneﬁt in
patients with rIA at lower cost of drug therapy.
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OBJECTIVE: The “AIDS epidemic update” (2007) published
by the United Nations (UN) and World Health Organization
(WHO), reports lower estimates of incidences of persons
infected with HIV globally. This study evaluates the cost
savings of these lower estimates on costs associated with
patients being treated by antiretroviral (ARV) drugs and oppor-
tunistic infection (OI) prophylaxis. METHODS: Estimated dif-
ferences in incidences of persons infected with HIV for the
eight global regions in years 2006 and 2007 were calculated
from UN reports. This difference was then multiplied by the
average percentage of patients on ARV and OI treatment.
Further, to derive the total cost savings associated with the
ARV cohort, the number of patients on ARV medication was
multiplied by a weighted average of ﬁrst and second line ARV
drug costs, lab costs, counseling costs, inpatient costs and out-
patient costs, for each region. Conversely, only counseling and
OI drug costs were included in the total cost of patients receiv-
ing OI prophylaxis treatment, for each region. Costs were
reported in 2006 US dollars. Sensitivity analysis performed on
all key parameters. RESULTS: The reduction of incidences of
persons infected with HIV from 2006 to 2007 resulted in a
total cost savings of $309.5 million, or 42%. Separately, the
patients being treated by ARV drugs attributed a cost savings of
$274.7 million, contrary to patients on OI drugs attributing
$34.8 million to cost savings. The greatest savings were shown
in the Sub-Saharan Africa region ($191.1 million). CONCLU-
SION: Based on the revised estimates, the worldwide savings is
a large percentage of the treatment budget. Notwithstanding
increased incidence rates in subsequent years, these savings
should continue beyond 2007.
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OBJECTIVE: Restricted information exists to guide clinicians in
selecting antibiotics for diabetic foot infections in Colombia.
Because this serious complication causes substantial morbidity,
mortality, and incurs major health care costs, we developed a
decision tree model to determine, from the Ministry of Health’s
perspective, the cost-effectiveness in Colombia of the treatments
recommended by the Infectious Diseases Society of America
guidelines for mild diabetic foot infections. METHODS: A
decision-tree model was developed using TreeAge® Pro-2007
and clinical experts. Success probabilities were derived from
published randomized controlled trials. Drug costs were
obtained from the Farmaprecios Guía de precios sugeridos al
público, promedio del mercado para farmacias independientes.
No 98 September–Octuber 2007. Thomson PLM. S.A. Bogotá
D.C. and amputation and hospitalization costs from ISS 2001/
2004 database, with values adjusted to 2007 using the Colom-
bian inﬂation. One-way and two-way sensitivity analyses were
performed to test the robustness of the decision tree model by
varying the clinical success rates and costs of antibiotics. Proba-
bilistic sensitivity analyses were also performed using Monte
Carlo simulations. RESULTS: Clindamycin was cost-effective,
dominating all other choices, and cephalexin had the next best
proﬁle. Expected success rates were 99.4% for clindamycin,
97.8% for cephalexin, 95.4% for amoxicillin-clavulanate,
95.2% for oxacillin and 95.0% for levoﬂoxacin. The expected
cost of clindamycin ($315,200 pesos (USD$157.28)) was lower
than the next best alternative, cephalexin $366,560 pesos
(USD$182.14); a cost difference of $51,360 pesos (USD$24.86)
per patient treated. However, success rates were based on a single
small trial for each drug (n < 30 for each). In sensitivity analyses,
the model/decision was sensitive to changes in efﬁcacy rates and
costs within plausible ranges for clindamycin and cephalexin.
CONCLUSION: Clindamycin was cost-effective in treating mild
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